<DOC>
	<DOCNO>NCT00451464</DOCNO>
	<brief_summary>Cardiovascular-related disease majority lead ten cause death Taiwan . Atherosclerotic cardiovascular disease multifactorial . Some non-modifiable risk factor ( e.g . genetic trait ) may attenuate benefit risk modification modifiable factor ( e.g . effect drug treatment ) . Genetic epidemiology widely use analyze underline risk cardiovascular disease point direction treatment prevention . Lipoprotein compose lipid protein . The genetic variation mutation apolipoprotein , protein lipoprotein , link lipid abnormality result severe atherosclerotic cardiovascular disease . ApoA-I , apo A-II , apo A-IV , apo B100 , apo B48 , apo C-I , apo C-II , apo C-III , apo D , apo E currently think affect lipid abnormality . In addition , document genetic variation present among different race . Apolipoprotein genetic variation genetic polymorphism study emerge important role field genetic therapy . The purpose 3-year study continue lipid study laboratory , identify apolipoprotein genotyping pooled hyperlipidemic patient normal control subject live Taiwan . We observe incidence link apo A-I , apo A-II , apo A-IV apo C-III genetic variation relate lipid abnormality cardiovascular disease . The change genotyping lipid lower drug treatment use statin fibrate hypercholesterolemic hypertriglyceridemic patient another goal project .</brief_summary>
	<brief_title>Studies Apolipoprotein Genotyping Drug Treatment Hyperlipidemic Patients</brief_title>
	<detailed_description>Cardiovascular-related disease majority lead ten cause death Taiwan . Atherosclerotic cardiovascular disease multifactorial . Some non-modifiable risk factor ( e.g . genetic trait ) may attenuate benefit risk modification modifiable factor ( e.g . effect drug treatment ) . Genetic epidemiology widely use analyze underline risk cardiovascular disease point direction treatment prevention . Lipoprotein compose lipid protein . The genetic variation mutation apolipoprotein , protein lipoprotein , link lipid abnormality result severe atherosclerotic cardiovascular disease . ApoA-I , apo A-II , apo A-IV , apo B100 , apo B48 , apo C-I , apo C-II , apo C-III , apo D , apo E currently think affect lipid abnormality . In addition , document genetic variation present among different race . Apolipoprotein genetic variation genetic polymorphism study emerge important role field genetic therapy . The purpose 3-year study continue lipid study laboratory , identify apolipoprotein genotyping pooled hyperlipidemic patient normal control subject live Taiwan . We observe incidence link apo A-I , apo A-II , apo A-IV apo C-III genetic variation relate lipid abnormality cardiovascular disease . The change genotyping lipid lower drug treatment use statin fibrate hypercholesterolemic hypertriglyceridemic patient another goal project . Our result show ApoC-III ( 3175NT C→G ) mutation significantly relate hypertriglyceridemia , relation also find Apo B exon 29 ( 13132 NT C→G ; 4311 AA Asn →Ser ) mutation . It interesting find hot spot mutation among Caucasian population , Apo B exon 26 ( 10699 NT C→A ; 3500 AA Arg →Gln ) , Apo A-IV ( 1527-2345 NT ) Apo E exon 2 mutation , find test sample . Most presented allele frequency apolipoteins gene different population Caucasian population . The present result strongly suggest necessary establish genetic data link disease .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Hyperlipidemia Liver kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Apolipoprotein , Gene polymorphism , Hyperlipidemia</keyword>
</DOC>